Trials / Completed
CompletedNCT00709540
A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · Industry
- Sex
- Female
- Age
- 45 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ACE-011 in healthy postmenopausal women.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ACE-011 or placebo | multiple administrations of ACE-011 given subcutaneously once per month for 3 months (4 administrations total) |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2008-07-03
- Last updated
- 2021-07-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00709540. Inclusion in this directory is not an endorsement.